Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07052604
Recruiting Observational

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

NCT07052604 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de Saint-Denis
Phase
Observational
Started
2023-12-15
Last updated
2025-07-04

Condition(s) studied

Pneumonia, Ventilator-AssociatedStenotrophomonas MaltophiliaIntensive Care UnitsAnti-Bacterial AgentsDrug Resistance, Bacterial

Study summary

This study looks at how different antibiotic treatments affect patients in intensive care who have pneumonia caused by the bacteria Stenotrophomonas maltophilia. It compares using one antibiotic versus two antibiotics, and treatment lengths of 7 days versus 14 days, to see which approach helps patients survive better. The study also examines how resistant the bacteria are to antibiotics and how often the pneumonia comes back.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients (age ≥ 18 years) * Hospitalized in Medical Intensive Care Unit between January 1, 2018, and December 31, 2023 * Intubated and mechanically ventilated * Diagnosed with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia Exclusion Criteria: * Patients under 18 years old * Patients who refuse the use of their data for research purposes

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier de Saint-Denis Saint-Denis France Recruiting

More Centre Hospitalier de Saint-Denis trials in France

Representation of Diet in the Management of Type 2 Diabetes in Migrant Patients at CHSD Recruiting
Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children" Recruiting
Medical Anthropology and Migrants in Precarious Situations, Cared for in Intensive and Post-intensive Care Units Starting soon
Community-acquired Pneumonia Due to Chlamydia Pneumoniae Starting soon
Geographic Analysis of Cancer Patients' Residences at Delafontaine Hospital Starting soon

Other trials for the same condition

Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation Recruiting
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients Recruiting
Non-Invasive Blood Pressure Monitoring in ICU Patients Using the DARE Device Recruiting
Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia Recruiting
Prevalence of Carriage of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteria in Preterm Premature Rupture of Membranes : A French Multicenter Cohort Study Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07052604 on ClinicalTrials.gov ↗ ← All trials in France